Merck KGaA Acquires Bio-Techne for $11.5 Billion to Expand Life Science Workflow Solutions
German pharma conglomerate makes third-largest acquisition to boost consumables-led portfolio and cell therapy manufacturing capabilities
Merck KGaA announced a definitive agreement to acquire Bio-Techne Corporation for $73 per share, representing an enterprise value of $11.5 billion and a 35% premium to Bio-Techne's unaffected share price of $54. The deal marks Merck's third-largest acquisition in company history and signals a decisive push to expand its Life Science business across the discovery-to-manufacturing value chain.
Group CEO Kai Beckmann emphasized this is "not a financial engineering exercise" but rather a strategic transaction that builds on Merck's strengths. The acquisition targets immediate sales growth accretion for the Merck Group following closing, with Life Science-specific growth accretion expected by 2028. More importantly, the transaction is projected to deliver EBITDA pre margin accretion immediately after closing, even before synergies fully materialize.
Cell Therapy Manufacturing Emerges as Strategic Priority
Beyond the immediate portfolio expansion, the deal positions Merck to enter the high-growth cell therapy manufacturing market through Bio-Techne's Wilson Wolf subsidiary. Bio-Techne currently owns 20% of Wilson Wolf, with an option to acquire the remaining 80% by 2028 based on 2027 financial performance. The buyout is structured at 4.4 times revenue with a maximum price of EUR 1 billion.
Life Science CEO Jean-Charles Wirth highlighted particular enthusiasm for Wilson Wolf's G-Rex platform, which provides differentiated tools and consumables supporting customers from R&D through commercial-scale manufacturing. When asked about cell therapy market dynamics, Wirth noted the company sees "positive and good activities in cell therapy improvement," though he declined to elaborate on specific pipeline developments driving the investment thesis.
The Wilson Wolf option represents a derivative under IFRS accounting and will be recognized in EBITDA, requiring fair value accounting until potential execution. CFO Helene von Roeder confirmed Bio-Techne does not currently consolidate Wilson Wolf's financials.
Highly Consumable-Focused Portfolio Provides Recurring Revenue
Bio-Techne's business model offers compelling economics, with consumables representing approximately 81% of sales, creating what Wirth characterized as a "highly durable and recurring revenue profile." The company has demonstrated impressive momentum over six years, growing sales from $714 million in fiscal 2019 to $1.2 billion in fiscal 2025, while adjusted operating income increased from $244 million to $384 million.
The acquisition targets three high-growth markets with a combined total addressable market of $27 billion. Advanced therapy manufacturing, including targeted protein degradation and cell therapy, is expected to grow above 20% annually. Discovery of novel biology insights, addressed through cell-based systems including organoids, is growing at high single-digit rates. The enabling of precision diagnostics market, featuring spatial multiomics technologies, is expanding at mid-single-digit rates.
Beckmann pointed to Bio-Techne's "appealing growth and margin profile" with management expecting high single-digit growth over the medium term. When pressed on revenue synergies, both Wirth and von Roeder emphasized these are not included in financial projections, though Wirth acknowledged opportunities to leverage Merck's global footprint and omnichannel approach, particularly in EMEA and Asia Pacific where Bio-Techne has historically been underweighted versus the Americas.
Financial Structure Maintains Discipline Within Stated Guardrails
The transaction values Bio-Techne at 23.2 times enterprise value, declining to 17.5 times when including EUR 140 million in targeted run-rate cost synergies, which represent approximately 12% of Bio-Techne's sales. Von Roeder characterized this synergy level as comparing "favorably with industry benchmarks" while noting it already sits at the high end of typical ranges.
The EUR 140 million in cost synergies are expected to be fully realized by year three after closing, with a linear ramp-up. One-time integration costs are estimated at EUR 500 million, split between roughly EUR 200 million in transaction costs and EUR 300 million in integration costs, distributed across years one and two. Management expects EPS pre accretion by year three after closing.
Financing will combine cash and new U.S. dollar and euro-denominated debt at an average interest rate between 4% and 5%. Net debt to EBITDA is expected to remain below 3.0 times, with rapid deleveraging anticipated given Merck's strong cash generation profile. When questioned why the 4-5% cost of debt assumption appeared elevated given current rates, von Roeder did not provide additional detail but reaffirmed confidence in the financing structure.
Beckmann explained the timing by noting the valuation "wasn't possible 2 years ago," suggesting Bio-Techne's recent stock performance created an attractive entry point. He declined to comment when asked whether Merck competed in a process or negotiated bilaterally with Bio-Techne.
Portfolio Complementarity Creates Cross-Selling Opportunities
Wirth emphasized the "very, very limited overlap" between portfolios, with Bio-Techne's capabilities spanning reagent solutions, precision diagnostics, spatial biology and analytical solutions fitting alongside Merck's existing Discovery Solutions, Advanced Solutions and Process Solutions businesses. The majority of Bio-Techne's operations will be integrated into Discovery Solutions, though all three divisions are expected to benefit.
Specific synergies were highlighted with last year's acquisitions, including potential integration with Mirus Bio in transfection technologies and HUB organoid business. Bio-Techne's characterization and quantification capabilities for proteins, quality control testing, and support for diagnostic development complement Merck's existing strengths in reagents, immunochemistry, biochemicals and cell biology tools.
Wirth outlined a "thoughtful and phased approach to integration" modeled on previous large deals including Millipore, Sigma-Aldrich and Versum, prioritizing business continuity, talent retention, customer relationships and innovation. Management noted Merck's U.S. presence includes over 14,000 employees across 58 sites, with more than 30 U.S. manufacturing facilities. The addition of Bio-Techne will "enhance resilience and expand our capabilities within the U.S.," according to Beckmann.
Academia Exposure Presents Near-Term Headwind
Bio-Techne derives approximately 20% of revenue from academia, a segment that has faced headwinds in recent years. While Wirth acknowledged the market has been "muted or changing," he expressed confidence that "we are at a stage where we reach a bottom" with the outlook becoming "slightly more attractive" going forward. He emphasized academia's importance as a "highly, highly innovative" segment despite current challenges.
When pressed on margin expansion potential, particularly given Bio-Techne's slight margin contraction between 2019 and 2025, von Roeder declined to provide specific guidance, noting the company cannot comment extensively on Bio-Techne's standalone numbers and directing investors to consensus expectations, with which management is "broadly comfortable."
The transaction remains subject to customary closing conditions including regulatory approvals and Bio-Techne shareholder approval, with closing anticipated by end of 2026 or early 2027. Beckmann framed the deal within Merck's broader strategic focus as a growth company, noting "growth comes from Life Science and Electronics, and this is where the M&A focus lies," while Healthcare's strong cash flow profile enables faster deleveraging to support continued dealmaking.